We previously demonstrated that RB18A, a member of TRAP220/DRIP205/PBP family, in vivo acted as a cofactor of transcription by dierently regulating p53wt transactivating activity on physiological promoters. Using p53-negative cells transfected with dierent constructs, we herein demonstrated that RB18A downregulated p53wt-dependent apoptosis. This biological regulation was due to a speci®c diminution of p53wt protein level, as level of p53mut and GAPDH proteins was not modi®ed. This p53wt diminution was dependent on proteasome activity, as inhibited by MG-132 inhibitor. This speci®c p53wt degradation was correlated with an increase in expression of MDM2, which promoted p53wt degradation into proteasome. RB18A up-regulated MDM2 expression by activating MDM2 promoter, even in absence of p53wt. Altogether, these data emphasized that RB18A could regulate p53wt function not only by direct interaction between both proteins, but also by up-regulating promoter activity of MDM2, a p53-regulating partner.
RB18A is a human gene, which codes for a protein characterized by an apparent molecular weight of 205 kDa (Drane et al., 1997) . Cloning and sequencing RB18A cDNA led us to demonstrate that, while no signi®cant homology was found between RB18A and p53 nucleotide sequences, both molecules shared antigenic relationship, as RB18A was recognized by three dierent anti-p53 monoclonal antibodies (moAb): PAb1801, PAb421 and DO1. In vitro, RB18A selfoligomerized and interacted with p53 protein. These binding properties and the epitope recognized by PAb1801 moAb were carried by RB18A C-terminal domain (Drane et al., 1997) . Recently, we demonstrated (Frade et al., 2000) that in vivo RB18A directly interacted also through its C-terminal domain with wild type p53 (p53wt) and acted as a cofactor of transcription by dierently regulating p53-transactivating activity on promoters of Bax, p21Waf1 and IGF-BP3 genes. Indeed, interaction of RB18A with p53wt activated Bax promoter and inhibited p21Waf1 or IGF-BP3 promoters, while in absence of p53wt, RB18A did not regulate the activity of these three promoters (Frade et al., 2000) . RB18A gene was localized on chromosome 17q12-q21.1 (Frade et al., 2000) , a locus associated with human cancers and especially with breast and colon cancers.
Human RB18A shared structural, gene localization and functional properties with other cellular components, as 165 kDa murine PBP (peroxisome proliferator-activated receptor (PPAR)-binding protein), which acted as a co-activator of nuclear receptors (Zhu et al., 1997) . TRAP220 (Yuan et al., 1998a,b) and DRIP205 , two human genes identi®ed later than RB18A, also shared up to 98% identity with RB18A nucleotide sequence. TRAP220, a 220 kDa thyroid hormone receptor-associated protein (Yuan et al., 1998a,b) and DRIP205, a 205 kDa vitamin D receptor interacting protein , both belong to multiple 12 to 15 subunit complexes, namely TRAP and DRIP complexes respectively. As PBP (Zhu et al., 1997) , TRAP220 (Yuan et al., 1998a; Ito et al., 1999) and DRIP205 directly interacted, through two dierentially preferred LXXLL regions (Ren et al., 2000) , with distinct hormoneactivated nuclear receptors: i.e. thyroid hormone receptor (THR), vitamin D receptor (VDR), retinoic acid receptor alpha (RARa), retinoic X receptor (RXR), RORa , PPARg (Kodera et al., 2000) and glucocorticoid or estrogen receptors (Burakov et al., 2000; Warnmark et al., 2001) . Thus, PBP/TRAP220/DRIP205 acted as bridging co-activators of the basal transcription machinery . TRAP220 was also demonstrated to interact with p53wt (Ren et al., 2000) , as RB18A (Drane et al., 1997) . PBP gene was also localized on chromosome 17q12 (Zhu et al., 1999) . The existence of a RB18A/TRAP220/DRIP205/PBP gene family sharing sequence homologies was also supported by FISH mapping analysis, which demonstrated labeling of two loci on the same chromosome 17q12-q21.1 (Frade et al., 2000) . The biological importance of this gene family was demonstrated as ablation of murine TRAP220 gene revealed that null mutants died Oncogene (2002) (Ito et al., 2000) . PBP null mutation [PBP(7/7)] was also embryonically lethal at embryonic day 11.5 (Zhu et al., 2000) . Thus, human RB18A/TRAP220/DRIP205/PBP, by sharing 98% nucleotide sequence identity, similar binding properties and gene localization, represented either an Figure 1 RB18A down-regulates p53wt-dependent apoptosis. 10 6 K562 cells were transfected by electroporation, as previously described (Frade et al., 2000) , with 3 mg pCMV-p53wt (kindly provided by Dr B Vogelstein) in absence (A) or in presence of 6 mg pCMV-RB18A (Drane et al., 1997; Frade et al., 2000) (B). In control, cells were transfected with pCMV alone (C) or pCMV-RB18A alone (D). Transfected cells were washed, ®xed with 70% ethanol, rehydrated, resuspended in PBS containing 0.1% Triton X-100 and then incubated with anti-p53 PAb240 moAb at 1 mg/ml PBS at 378C for 1 h. After washing, cells were incubated with FITC conjugated goat anti-mouse Ig (10 mg/ml) for 1 h at 378C. Washed cells were resuspended in 1 ml PBS containing 50 mg RNase and 50 mg propidium iodide, for a further 20 min incubation at 378C. Flow cytometry analysis was performed with ā uorescence activated cell sorter (Coulter Epics Elite). Laser excitation was at 488 nm and ®lters for FITC and propidium iodide were 525 and 630 nm, respectively. Apoptosis was measured at 48 h and 72 h post-transfection. In A, B, C and D, the dotted line corresponds to the p53-positive cells observed at 72 h. The grey peaks correspond to cells in G1, S and G2 phase (from left to right). The amount of sub-G1 apoptotic cells was quanti®ed and represented in E. This ®gure is representative of ®ve dierent experiments RB18A role in p53-apoptosisidentical molecule or isoforms of the same molecule, at least belonging to the same family of molecules.
To further investigate the biological properties of RB18A, we herein analysed whether RB18A could regulate p53-dependent apoptosis. For this purpose, two human p53-null cell lines, K562 cells (an erythroleukemia cell line) and H1299 (pulmonary embryo carcinoma) were transfected with p53wt cDNA in the presence or absence of RB18A cDNA, as previously described (Frade et al., 2000) . Two dierent analytical methods were used to measure cell apoptosis: ow cytometry and endonuclease activity. In¯ow cytometry analysis, percentage of apoptotic cells was determined by double staining of transfected cells, using propidium iodide for cell DNA and PAb240 antip53 moAb, followed by an FITC conjugated second antibody, for p53 detection. P53-positive apoptotic K562 cells were determined by analysing green uorescence after gating the cell debris ( Figure 1 Figures 1 and 2 were obtained using H1299 cell line (data not shown). Thus, using two dierent analytical methods, we demonstrated that RB18A over-expression down-regulated p53-dependent apoptosis. These data led us to analyse whether the level of p53 protein expression was modi®ed when p53-dependent apoptosis was induced in transfected cells. For this purpose, equal amounts of 1% NP40 solubilized proteins from K562 transfected cells were submitted to SDS ± PAGE, transferred to nitrocellulose sheets, then analysed by immunoblotting using the respective moAb. When K562 cells were co-transfected with p53wt and RB18A cDNAs ( Figure 3A1 , lane 5), a 60% diminution was observed in p53wt protein level when compared to cells transfected with p53wt alone (lane 2). Interestingly, the level of p53mut was not signi®cantly modi®ed in cells co-transfected with p53mut and RB18A cDNAs (lane 6) as compared to cells transfected with p53mut alone (lane 3). In control, the amount of endogenous GAPDH remained identical in all samples ( Figure 3A2 , lanes 1 ± 6). In addition ( Figure 3D ), the level of endogenous (lanes 1 and 3) or exogenous (lanes 2 and 4) RB18A was not modi®ed in K562 cells transfected with p53wt. Similar results were obtained using H1299 cell line (data not shown). Thus, RB18A over-expression induced a speci®c diminution of p53wt protein level, as compared to the stable level of p53mut or GAPDH proteins.
As p53wt, p53mut and RB18A cDNAs were all driven by the same CMV promoter in the two p53-null cells used, this speci®c diminution of the p53wt protein level induced by RB18A suggested a possible degradation of p53wt. It has been demonstrated by others (Haupt et al., 1997; Oren, 1999 ) that p53wt degradation was promoted into the proteasome under the control of MDM2 protein. These data led us to analyse the possible involvement of MDM2 in RB18A regulation of p53wt degradation. First, we analysed whether MG-132, a speci®c proteasome inhibitor, had any eect on the p53wt diminution induced by RB18A. When H1299 cells were co-transfected with p53wt and RB18A ( Figure 3B1, lanes 2 and 4) , treatment with MG-132 (lane 4) totally abolished the p53wt decrease induced by RB18A (lane 2). In control, the amount of GAPDH remained identical in all samples ( Figure  3B2 ). Similar results were obtained using K562 cells (data not shown). Second, the level of endogenous MDM2 protein was also analysed in these same transfected cells. Total solubilized proteins from these cells were separated by SDS ± PAGE and immunoblotted using anti-MDM2 Ab. Transfection with p53wt cDNA increased endogenous MDM2 expression (FigFigure 2 RB18A down-regulates the endonuclease activity induced by p53wt. 10 6 K562 cells were transfected for 48 h with 3 mg pCMV-p53wt (row 2), 3 mg pCMV-p53mut (containing p53 mutated in position 175 and devoid of transactivating activity (Kern et al., 1992) , kindly provided by Dr M. Bar-Eli) (row 3), 6 mg pCMV-RB18A (row 4), 6 mg pCMV-RB18A in presence of 3 mg pCMV-p53wt (row 5) or 3 mg pCMV-p53mut (row 6). Non transfected cells (row 1) and positive control (row 7) were used as control. Cells were then collected by centrifugation, washed in PBS and further treated to measure endonuclease activity, using an ELISA assay with the`Cell death detection ELISA plus ' kit (Roche Diagnostics), as described by the manufacturer, with cell lysate of 10 4 cells in 20 ml. Color development was measured at 405 nm in a microplate reader. Positive control, which gave the 100% value for apoptosis, was DNA-histone complex, included in this kit. This ®gure is representative of four dierent experiments ure 3C1, lane 2), while p53mut cDNA did not signi®cantly modify endogenous MDM2 expression (lane 3). This result is in agreement with data published by others (Haupt et al., 1997; Oren, 1999) . However, when K562 cells were transfected with RB18A cDNA alone, endogenous MDM2 expression was also increased twofold (lane 4). This increase was not modi®ed when cells were co-transfected with RB18A and with either p53wt (lane 5) or p53mut (lane 6) cDNAs. Analysis by RT ± PCR ( Figure 3E ) of the level of endogenous MDM2 transcript in cells transfected Non transfected cells (lane 1) were used as control. Non transfected or transfected cells were collected by centrifugation and lyzed for 30 min at 48C in buer containing 50 mM Tris (pH 7.6), 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, protease inhibitors as 1 mM PMSF, 60 mm EACA, 12.5 mM benzamidine and 12.5 mM iodoacetamide. Solubilized proteins were collected by centrifugation at 15 000 g for 15 min. Protein content was normalized after a BCA assay. Then, 50 mg solubilized proteins were run on SDS ± PAGE and immunoelectrotransferred. Immunodetection was performed, as previously described (Barel et al., 1989) , with DO1, an anti-p53 moAb (A1) at 0.05 mg/ml, anti-GAPDH moAb diluted 1/40,000 (A2 and C2) and Ab-4, an anti-MDM2 moAb (Oncogene, MA) at 1 mg/ml (C1). (B) 10 6 H1299 cells were transfected by calcium phosphate coprecipitation method, as previously described (Frade et al., 2000) , for 22 h with 3 mg pCMV-p53wt, in absence (lanes 1 and 3) or in presence (lanes 2 and 4) of 6 mg pCMV-RB18A. Then, 100 mM MG-132, a speci®c proteasome inhibitor was added for 22 h post-transfection for 2 h (lanes 3 and 4), as described by others (Haupt et al., 1997) . Then, solubilized proteins were submitted to 7% SDS ± PAGE under reducing conditions, electrotransferred and immunoblotted, using DO1, an anti-p53 moAb (B1) or mAB374, an anti-GAPDH moAb (Chemicon, CA, USA) (B2). (D) K562 cells were transfected, in the experimental conditions described above, with RB18A cDNA (lanes 2 and 4) H1299 cells were transfected with 3 mg pMDM2-NA-CAT, which contained the minimal p53-responsive promoter of MDM2, kindly provided by Dr M Oren (lanes 1 to 4) . Some of them were co-transfected with 3 mg pCMV-p53wt (lane 2), 3 mg pCMVp53mut (lane 3) or with 6 mg pCMV-RB18A (lane 4). In control, cells were transfected with 3 mg IGF-BP3 CAT, prepared in our laboratory (Frade et al., 2000) in absence (lane 5) or in presence of 6 mg pCMV-RB18A (lane 6). Normalization of transfection eciency was performed by adding pCMV-b Gal plasmid diluted 1/20. MDM2 CAT or IGF-BP3 CAT activity was analysed on Thin Layer Chromatography plates (A) and quanti®ed by Liquid Scintillation Counting (B), as previously described (Frade et al., 2000) . This experiment is representative of ®ve dierent experiments RB18A role in p53-apoptosiswith RB18A cDNA demonstrated a good correlation in increased expression of MDM2 transcript and protein. In control, endogenous GAPDH amount remained identical in all samples ( Figure 3C2 ). Third, identical results were obtained when H1299 or K562 cells were also transfected with MDM2 cDNA in addition to RB18A and p53wt cDNAs (data not shown). The increase in MDM2 expression triggered by RB18A led us to analyse whether RB18A could regulate MDM2 promoter. Even in absence of p53wt in K562 cells, RB18A over-expression strongly enhanced MDM2 promoter activity (Figure 4, lane 4) , at the same level as p53wt (lane 2). This strong enhancement of MDM2 promoter activity was unchanged when cells were co-transfected with RB18A and p53wt cDNAs (data not shown). In control, the activity of MDM2 promoter was not modi®ed by p53mut (lane 3) as compared to p53wt alone (lane 2), in agreement with data published by others (Oren, 1999) .
Thus, we herein demonstrated that RB18A downregulated p53wt-dependent apoptosis, as measured by the number of p53wt apoptotic cells and the endonuclease activity of p53wt transfected cells. This down-regulation by RB18A over-expression was correlated with a speci®c decrease of p53wt protein level in transfected human cells. The speci®city of this p53wt protein level diminution was supported by the absence of such eect on p53mut or GAPDH protein level in cells transfected in the same conditions. Data also supported that this regulation by RB18A was not due to its property to interact directly with p53wt, but to its eect on the expression of MDM2, another p53wt regulating protein. Indeed, RB18A up-regulated MDM2 protein expression by activating MDM2 promoter, even in absence of p53wt. This property adds a new function to RB18A, which was previously shown to regulate the activity of physiological promoters, as Bax, p21Waf1 and IGF-BP3, only through its interaction with p53wt (Frade et al., 2000) . While the exact mechanisms through which RB18A regulates MDM2 promoter remain unknown, the following points should be taken into account: (a) in preliminary experiments, using electrophoretic mobility shift assay, we could not detect any speci®c binding of RB18A recombinant protein on MDM2 promoter (data not shown); (b) RB18A, being a member of the TRAP220/DRIP205/PBP family, could act as cofactor of the transcriptional machinery by interacting with multiple partners and consequently modulating dierently distinct promoters (Frade et al., 2000; Ito et al., 1999; Atkins et al., 1999; Kodera et al., 2000; Burakov et al., 2000; Warnmark et al., 2001) . This is well illustrated by the apparent discrepancy in RB18A properties in dierently regulating p53-dependent apoptosis: indeed, while we herein demonstrated that RB18A activated MDM2 promoter and consequently inhibited p53-dependent apoptosis, we previously demonstrated that RB18A, by acting as p53-cofactor, activated Bax promoter, this activation triggering an increase in p53-dependent apoptosis (Frade et al., 2000) . Such dierence in RB18A role in p53-dependent apoptosis could be due to the variation in expression level of RB18A, p53wt and/or unknown transcription factor and consequently to the molar ratio of RB18A/p53wt and/or RB18A/unknown transcription factor regulating MDM2 promoter. Further studies are needed to identify the other transcription factor(s) through which RB18A regulated MDM2 promoter, independently of p53wt. In addition, the p53wt diminution triggered by RB18A over-expression was related to MDM2 over-expression and to the proteasome activity, as addition of MG-132, a speci®c proteasome inhibitor, totally restored the level of p53wt in cells co-transfected with RB18A. Therefore, we suggest that, in the regulatory loop which exists between MDM2 and p53wt, i.e. p53wt enhanced MDM2 promoter activity, thus inducing an increase in MDM2 protein expression (Oren, 1999) . RB18A protein could act as a p53wt-substitute for activation of MDM2 promoter in cells where p53wt protein expression is partially or totally inhibited.
